Alembic Pharma Delivers Strong Revenue Growth in Q1FY27

💊

reported Q1FY27 consolidated net profit of ₹170 crore, up from ₹154 crore in the corresponding quarter last year. Revenue increased sharply to ₹2,150 crore from ₹1,710 crore, while the EBITDA margin softened to 15.44% from 16.45% despite strong top-line growth.